Bevacizumab in the treatment of NSCLC: patient selection and perspectives
Lung Cancer: Targets and Therapy · 2017-12 · Volume 8 · 259-269
DOI: 10.2147/lctt.s110306 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Lung Cancer: Targets and Therapy, 2017-12. Verfasst von Alessia E Russo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, San Vincenzo Hospital, Taormina (Messina), Italy. Die Arbeit wurde bisher 28-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology Department, San Vincenzo Hospital, Taormina (Messina), Italy.
- Laboratory of Translational Oncology & Functional Genomics, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
- Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA.
Zitieren
APA
Russo, A. E., Priolo, D., Antonelli, G., Libra, M., McCubrey, J. A., & Ferraù, F. (2017). Bevacizumab in the treatment of NSCLC: patient selection and perspectives. Lung Cancer: Targets and Therapy, Volume 8, 259-269. https://doi.org/10.2147/lctt.s110306
Vancouver
Russo AE, Priolo D, Antonelli G, Libra M, McCubrey JA, Ferraù F. Bevacizumab in the treatment of NSCLC: patient selection and perspectives. Lung Cancer: Targets and Therapy. 2017;Volume 8:259-269. doi:10.2147/lctt.s110306
BibTeX
@article{Russo2017,
author = {Russo, Alessia E and Priolo, Domenico and Antonelli, Giovanna and Libra, Massimo and McCubrey, James A and Ferraù, Francesco},
title = {Bevacizumab in the treatment of NSCLC: patient selection and perspectives},
journal = {Lung Cancer: Targets and Therapy},
year = {2017},
volume = {Volume 8},
pages = {259--269},
doi = {10.2147/lctt.s110306}
}
EUVIMED